Common use of Annual Progress Report Clause in Contracts

Annual Progress Report. No later than ninety (90) days after December 31 of each calendar year, LICENSEE shall provide to BCM a written annual progress report describing progress on all research and development and commercial activities, during the most recent twelve (12) month period ending December 31 and plans for the forthcoming year (“Annual Progress Report”). If multiple technologies are covered by the license granted hereunder, the progress report shall provide the information set forth above for each technology. At BCM’s request, LICENSEE shall also provide any reasonable additional data BCM requires to evaluate LICENSEE’s or its Sublicensee’s performance of its obligations under Section 3.

Appears in 2 contracts

Samples: Exclusive License Agreement (Acer Therapeutics Inc.), Exclusive License Agreement (Opexa Therapeutics, Inc.)

AutoNDA by SimpleDocs

Annual Progress Report. No later than ninety (90) days [***] after December 31 of each calendar year, LICENSEE shall provide to BCM a written annual progress report describing LICENSEE's progress on all research and development and commercial activities, during the most recent twelve (12) month period ending December 31 and plans for the forthcoming year (“Annual Progress Report”). If multiple technologies are covered by the license granted hereunder, the progress report shall provide the information set forth above for each technology. At BCM’s request, LICENSEE shall also provide any reasonable additional data BCM requires to evaluate LICENSEE’s or its Sublicensee’s performance of its obligations under Section 3performance.

Appears in 1 contract

Samples: Exclusive License Agreement (Allovir, Inc.)

Annual Progress Report. No later than ninety (90) days [***] after December 31 of each calendar year, LICENSEE shall provide to BCM a written annual progress report describing LICENSEE’s progress on all research and development and commercial activities, during the most recent twelve (12) month period ending December 31 and plans for the forthcoming year (“Annual Progress Report”). If multiple technologies are covered by the license granted hereunder, the progress report shall provide the information set forth above for each technology. At BCM’s request, LICENSEE shall also provide any reasonable additional data BCM requires to evaluate LICENSEE’s or its Sublicensee’s performance of its obligations under Section 3performance.

Appears in 1 contract

Samples: Exclusive License Agreement (Allovir, Inc.)

Annual Progress Report. No later than ninety (90) days [***] after December 31 of each calendar year[***], LICENSEE shall provide to BCM a written annual progress report describing progress on all research and development and commercial activities, during the most recent twelve (12) month period ending December 31 [***] and plans for the forthcoming year (“Annual Progress Report”). If multiple technologies are covered by the license granted hereunder, the progress report shall provide the information set forth above for each technology. At BCM’s request, LICENSEE shall also provide any reasonable additional data BCM requires to evaluate LICENSEE’s or its Sublicensee’s performance of its obligations under Section 3sublicensee performance.

Appears in 1 contract

Samples: Exclusive License Agreement (Cara Therapeutics, Inc.)

AutoNDA by SimpleDocs

Annual Progress Report. No later than ninety (90) days [***] after December 31 of each calendar year[***], LICENSEE shall provide to BCM a written annual progress report describing progress on all research and development and commercial activities, during the most recent twelve (12) month period ending December 31 [***] and plans for the forthcoming year (“Annual Progress Report”). If multiple technologies are covered by the license granted hereunder, the progress report shall provide the information set forth above for each technology. At BCM’s request, LICENSEE shall also provide any reasonable additional data BCM requires to evaluate LICENSEE’s ’S or its Sublicensee’s performance of its obligations under Section 3sublicensee performance.

Appears in 1 contract

Samples: Exclusive License Agreement (Cara Therapeutics, Inc.)

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!